--- title: "Oculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS" description: "Oculis (NASDAQ:OCS) reported quarterly earnings of ($0.59) per share, missing estimates by $0.06. The company had revenue of $0.25 million, exceeding expectations of $0.14 million. Oculis has a negati" type: "news" locale: "en" url: "https://longbridge.com/en/news/254323363.md" published_at: "2025-08-24T12:28:47.000Z" --- # Oculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS > Oculis (NASDAQ:OCS) reported quarterly earnings of ($0.59) per share, missing estimates by $0.06. The company had revenue of $0.25 million, exceeding expectations of $0.14 million. Oculis has a negative return on equity of 92.95% and a negative net margin of 13,788.70%. Despite the earnings miss, Oculis stock rose 1.4% to $17.80. Analysts maintain a "buy" rating with target prices ranging from $32.00 to $35.67. Institutional investors hold 22.30% of the company's stock, indicating interest in the firm. Oculis (NASDAQ:OCS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06), Zacks reports. The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%. ## Oculis Stock Up 1.4% Oculis stock opened at $17.80 on Friday. Oculis has a 52 week low of $10.79 and a 52 week high of $23.08. The company's 50 day moving average price is $18.41 and its two-hundred day moving average price is $18.74. The stock has a market cap of $777.15 million, a P/E ratio of -6.74 and a beta of 0.27. ## Wall Street Analyst Weigh In A number of research analysts have issued reports on OCS shares. HC Wainwright boosted their target price on Oculis from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Friday. Chardan Capital upped their target price on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $35.67. **Check Out Our Latest Stock Analysis on Oculis** ## Hedge Funds Weigh In On Oculis Several institutional investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Oculis during the 2nd quarter valued at $393,000. Geode Capital Management LLC increased its stake in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock valued at $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock valued at $786,000 after buying an additional 878 shares during the last quarter. Hedge funds and other institutional investors own 22.30% of the company's stock. ## Oculis Company Profile (Get Free Report) Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. ## Further Reading - Five stocks we like better than Oculis - What does consumer price index measure? - Broadcom Named in Apple’s $100B U.S. Investment Plan - Golden Cross Stocks: Pattern, Examples and Charts - 3 Reasons Salesforce Is a Bargain Right Now - How to Profit From Value Investing - How ServiceNow Is Turning AI Strategy Into Real Revenue *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Oculis Right Now? Before you consider Oculis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list. While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [OCS.US - Oculis Holding AG](https://longbridge.com/en/quote/OCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Oculis 任命 Katie Kazem 为首席法律官 \| OCS 股票新闻 | Oculis Holding AG 任命 Katie Kazem 为首席法律官，增强其领导团队以推进神经眼科的后期资产。Kazem 拥有超过 15 年的公司治理和证券法经验，此前曾担任 Oculis 的外部顾问。首席执行官 Riad She | [Link](https://longbridge.com/en/news/276107792.md) | | Oculis Holding (OCS) 在 Privosegtor 获得 FDA 突破性认定后股价上涨了 15.3%，该药物用于治疗视神经炎 | Oculis Holding AG 的股票在美国 FDA 授予其候选药物 Privosegtor 突破性疗法认证后上涨了 15.3%，该药物旨在治疗视神经炎。这一认证得到了积极的二期临床试验结果的支持，使 Oculis 在神经眼科疾病领域成 | [Link](https://longbridge.com/en/news/272160619.md) | | Oculis (OCS)：Privosergtor 在视神经炎领域的突破性表现支持其首创药物的上行潜力和买入评级 | LifeSci Capital 分析师 Patrick Dolezal 对 Oculis (OCS) 股票维持 “买入” 评级，指出 privosergtor 在视神经炎方面的强大临床和监管特征。FDA 的突破性疗法认定突显了该药物超越现有 | [Link](https://longbridge.com/en/news/271687546.md) | | Oculis：临床和监管势头的增强支持买入评级及 42 美元目标价 | H.C. Wainwright 的 Yi Chen 对 Oculis Holding 维持买入评级，目标价为 42 美元，理由是其临床和监管前景强劲。FDA 对 privosegtor 在视神经炎中的突破性疗法认定突显了其市场潜力。Ocul | [Link](https://longbridge.com/en/news/271681406.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.